Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 5 Nov 2026
Promising but preliminary

Discordance of PD-L1 expression between primary and paired metastatic non-small cell lung cancer: a systematic review and meta-analysis.

Cancer cells in different body locations vary in immune markers, suggesting doctors may need multiple tissue samples for optimal treatment planning.

PD-L1 expression in non-small cell lung cancer (NSCLC) serves as a key predictive biomarker of response to immune checkpoint inhibitors; however, the concordance of PD-L1 expression between primary tumors and their corresponding metastatic lesions remains uncertain. Fifteen studies fulfilled the inclusion criteria, encompassing 1,029 matched primary-metastatic sample pairs from 1,014 patients with NSCLC.

What the study was

Study design
Meta-analysis
Population
Patients with (see abstract)
Sample size
14
Category
Treatment Innovation
Maturity
Validated
Journal
Frontiers in immunology

Why it surfaced

Meta-analysis (15 studies, 1,014 NSCLC patients) of PD-L1 expression discordance between primary and metastatic sites; directly impacts immunotherapy treatment decisions. Score=8/10.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.